An interventional study of EUS-guided transluminal drainage of necrotic collection in Pancreatitis, Acute Necrotizing, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Orlando Health, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Pancreatitis, Acute Necrotizing with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Pancreatitis, Acute Necrotizing · United States.
Among the 20 studies in Pancreatitis, Acute Necrotizing with a site in United States, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 20th registered.
75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.
Browse Pancreatitis, Acute Necrotizing studies →3 of the 20 studies in Pancreatitis, Acute Necrotizing with a site in United States are open now. Recruiting first, the newest first:
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18+
Orlando Health, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Pancreatitis, Acute Necrotizing studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 70 across 47 interventional studies indexed under Pancreatitis, Acute Necrotizing.
Median enrollment 40 across the 13 interventional studies, 31 across the 7 observational. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 20 have an industry lead sponsor. The 10 most frequent:
Orlando Health, Inc. is the lead sponsor of 28 studies on the registry; 10 are open to participants now.
Orlando Health, Inc. has 3 studies filed under Pancreatitis, Acute Necrotizing — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Pancreatitis, Acute Necrotizing with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Pancreatic necrosis complicates approximately 20-30% of severe acute pancreatitis cases. While many collections resolve without intervention, persistent symptomatic collections-particularly when infected-are associated with significant morbidity and mortality and frequently require procedural management. Current guidelines recommend delaying intervention until collections are fully walled off, typically around four weeks. However, in clinical practice, many patients deteriorate before this window is reached.
Prospective data from our institution, supported by recent meta-analyses, suggest that early intervention using modern endoscopic techniques can be performed safely, even when undertaken within the first four weeks of disease onset. We believe that, in appropriately selected patients, early endoscopic intervention may prevent clinical deterioration, reduce complications, shorten hospital stay, and decrease overall healthcare utilization compared with a delayed approach.
To formally evaluate this strategy, an international, multicenter randomized trial is being conducted, entitled Strategic Timing of Endoscopic Procedural Interventions in Infected Necrotizing Pancreatitis (STEP-IN Trial).
Acute pancreatitis imposes a significant burden on the US health-care system, resulting in approximately 300,000 hospital admissions annually and generating costs exceeding $2 billion. Necrotizing pancreatitis develops in approximately 20 to 30% of patients with acute pancreatitis. It can mature into a contained necrotic collection, typically four weeks into the disease course. While some collections may resolve without an intervention, persistent collections can result in symptoms such as pain, abdominal fullness restricting nutrition, vomiting due to gastric outlet obstruction, obstructive jaundice due to a large collection in the pancreatic head, new-onset or persisting organ failure, continued unwellness or infection that is associated with a mortality of 15-20%, and requires drainage and necrosectomy.
International guidelines recommend that, when possible, treatment should be delayed in patients with suspected or confirmed infected necrotizing pancreatitis, to allow for the collection to be walled-off with better demarcation and liquefaction of the necrosis, which generally takes around 4 weeks. The main rationale for postponement of an invasive intervention is to prevent complications, but this rationale originated from an era when open surgical necrosectomy was performed.
Recently, there has been a shift away from open surgery towards minimally invasive treatment approaches. The current standard approach for treatment is a minimally invasive step-up approach with percutaneous catheter or transluminal endoscopic drainage as the first step, followed by video-assisted retroperitoneal/sinus-tract or transgastric necrosectomy. The development of cautery-enhanced lumen-apposing metal stents (LAMS) for endoscopic drainage has significantly simplified the technical aspects of the procedure that facilitates its performance even in very sick patients.
Although international guidelines recommend postponing treatment until 4-weeks when the necrosis is better demarcated, in an international survey of expert pancreatologists, 45% of the respondents reported that they recommend immediate catheter drainage as soon as infected pancreatic and peripancreatic necrosis is diagnosed. In addition, a recent clinical practice guideline from the American Gastroenterological Association states that catheter drainage should be strongly considered when there is a concern of infection, even in the early phase of disease. However, a multicenter, randomized trial did not show superiority for immediate over postponed catheter drainage in reducing complications in patients with infected necrotizing pancreatitis.
Prospective data from our institution and from the meta-analysis suggest that interventions can be undertaken safely adopting state-of-the-art endoscopic methods even when the onset of pancreatitis is less than 4 weeks. Our data also suggest that although a significant proportion of patients undergoing early interventions (adopting an endoscopic approach) do not have a fully encapsulated collection, their treatment outcomes are not negatively impacted by such approach. If an early intervention, adopting an endoscopic approach, can be undertaken safely, it potentially can prevent further clinical deterioration and therefore complications, decrease length of hospitalization as patients may not have to wait for 3 to 4 weeks and overall treatment costs as compared to postponing the intervention until 4-weeks when the necrosis is fully walled-off.
The STEP-IN trial therefore is a natural step in the advancement of our understanding of timing of interventions in necrotizing pancreatitis as it answers an important clinical question: can early interventions be undertaken safely without subjecting patients to an arbitrary time frame of 4-weeks? In this study we challenge the existing paradigm of delayed intervention in attempt to further improve the clinical outcomes in patients with infected necrotizing pancreatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented or suspected infected necrotizing pancreatitis 1) Documented infected necrotizing pancreatitis, defined as: i. Positive culture obtained with percutaneous fine needle aspiration from the pancreatic necrotic collection (if intervention is undertaken ≤14 days of onset of acute pancreatitis) ii. OR gas in the necrotic collection on imaging at any time. 2) Suspected infected necrotizing pancreatitis, if >14 days after onset of disease, defined as: i. Persistent organ failure in patients admitted to the ICU ii. OR presence of at least three of the following six clinical/laboratory parameters (SIRS criteria or elevated CRP or elevated procalcitonin) with no other infection focus. These clinical criteria are considered sufficiently reliable only after the initial 14 days of acute pancreatitis:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the early treatment group, EUS-guided drainage is undertaken within 72 hours of randomization, earlier than 28 days after the onset of acute pancreatitis.
Procedure: EUS-guided transluminal drainage of necrotic collection
In the postponed treatment group, EUS-guided drainage is undertaken only from 28 days after the onset of acute pancreatitis when the collection is fully or predominantly walled-off (encapsulated).
Procedure: EUS-guided transluminal drainage of necrotic collection
EUS-guided drainage of the necrotic collection is performed by placement of a metal stent within the dominant collection.
Composite of major complications or death
Proportion of patients experiencing a major complication or death. Major complications comprise new onset organ failure, new onset systemic dysfunction, enteral or pancreatic-cutaneous fistula, intraabdominal bleeding, or visceral perforation.
Time frame: 6 months
Mortality
Proportion of patients with mortality from any cause
Time frame: 6 months
Major complications
Proportion of patients experiencing major complications. Major complications comprise new onset organ failure (respiratory, cardiovascular, renal, gastrointestinal, hepatic, hematologic, neurologic, or metabolic failure), new onset systemic dysfunction, enteral or pancreatic-cutaneous fistula, intraabdominal bleeding, or visceral perforation
Time frame: 6 months
New onset single and multiple organ failure
Proportion of patients with new onset failure of at least one organ system
Time frame: 6 months
New onset systemic dysfunction
Proportion of patients with worsening of any pre-existing medical condition
Time frame: 6 months
Enterocutaneous and pancreatic fistula
Proportion of patients with enterocutaneous fistula or pancreatic fistula. Enterocutaneous fistula is the formation of a fistula between the small bowel or colon and skin as indicated by feculent output from a percutaneous catheter or surgical wound site, confirmed on imaging or surgery. Pancreatic fistula is the formation of a fistula between the pancreas and skin as indicated by amylase-rich fluid output from a percutaneous catheter or surgical wound site, persisting after 3 months, and requiring specific treatment that include parenteral or enteral nutrition, antibiotics, somatostatin analogues and minimally invasive drainage.
Time frame: 6 months
Intraabdominal bleeding
Proportion of patients with intraabdominal bleeding. Intraabdominal bleeding is defined as bleeding within the intraabdominal cavity or gastrointestinal tract requiring interventional procedure
Time frame: 6 monthts
Visceral perforation
Proportion of patients with visceral perforation. Visceral perforation is defined as the perforation of a visceral organ requiring interventional procedure
Time frame: 6 months
Incisional hernia
Proportion of patients with incisional hernia. Incisional hernia is defined as herniation of intraabdominal structures through an area of weakness in the abdominal fascia, requiring surgical intervention or persisting at 6-month follow-up
Time frame: 6 months
Surgical site infection
Proportion of patients with surgical site infection. Surgical site infection is defined as the infection in superficial or deep layers of the abdominal wall at the site of prior intervention, as evident by the presence of purulent drainage or abscess on physical examination, imaging and/or requiring intervention
Time frame: 6 months
New onset diabetes
Proportion of patients with new onset diabetes. New onset diabetes is defined as new onset elevation in fasting plasma glucose ≥ 126 mg/dL, 2-hour plasma glucose ≥ 200 mg/dL after an oral glucose tolerance test or HbA1c ≥ 6.5%
Time frame: 6 months
New diagnosis of exocrine pancreatic insufficiency
Proportion of patients with new diagnosis of exocrine pancreatic insufficiency. Exocrine pancreatic insufficiency is defined as fecal elastase level \< 200μg/g in patients not previously taking pancreatic enzyme supplements
Time frame: 6 months
Procedure-related adverse events
Proportion of patients with any adverse event resulting from endoscopic or surgical intervention
Time frame: 6 months
Disease-related adverse events
Proportion of patients with any adverse event resulting from necrotizing pancreatitis
Time frame: 6 months
Number of interventions
Number of interventions performed for treatment of infected necrotizing pancreatitis including endoscopic, surgical and radiological interventions
Time frame: 6 months
Length of hospitalization
Length of hospitalization, including length of ICU stay
Time frame: 6 months
Readmissions
Proportion of patients with hospital admissions due to underlying disease or procedure-related adverse events
Time frame: 6 months
Presence of systemic inflammatory response syndrome (SIRS) at 72 hours post-index intervention
Proportion of patients with positive SIRS at 72 hours post-index procedure. Positive SIRS is defined by the presence of at least two of the following four criteria: 1. Body temperature \>100.4 °F or \< 96.8 °F 2. Heart rate \> 90 beats/minute 3. Respiratory rate \> 20 breaths/minute or PaCO2 \< 32mmHg 4. White blood cell count \> 12 or \< 4 x109/L or \> 10% immature neutrophils
Time frame: 72 hours
New onset systemic inflammatory response syndrome (SIRS) at 72 hours post-index intervention
Proportion of patients with new onset SIRS at 72 hours post-index intervention. Positive SIRS is defined by the presence of at least two of the following four criteria: 1. Body temperature \>100.4 °F or \< 96.8 °F 2. Heart rate \> 90 beats/minute 3. Respiratory rate \> 20 breaths/minute or PaCO2 \< 32mmHg 4. White blood cell count \> 12 or \< 4 x109/L or \> 10% immature neutrophils
Time frame: 72 hours
Resolution and improvement of systemic inflammatory response syndrome (SIRS) at 72 hours post-index intervention
Proportion of patients with resolution of SIRS at 72 hours post-index intervention. Positive SIRS is defined by the presence of at least two of the following four criteria: 1. Body temperature \>100.4 °F or \< 96.8 °F 2. Heart rate \> 90 beats/minute 3. Respiratory rate \> 20 breaths/minute or PaCO2 \< 32mmHg 4. White blood cell count \> 12 or \< 4 x109/L or \> 10% immature neutrophils
Time frame: 72 hours
Technical success
Rate of technical success. Technical success is defined as the successful completion of EUS-guided drainage of the necrotic collection
Time frame: 6 months
Treatment success
Rate of treatment success. Treatment success is defined as the resolution of necrotic collection on CT scan in association with clinical resolution of symptoms at 6 months from index intervention
Time frame: 6 months
Health-related quality of life (HRQoL)
Health-related quality of life (HRQoL) scores as assessed by the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36)
Time frame: 6 months
Overall treatment costs
Overall treatment costs from admission until hospital discharge. All relevant costs pertaining to treatment will be taken into consideration - procedure costs, cost of inpatient hospital stay (from date of procedure to discharge), cost of medications, cost of materials, cost of anesthesia, cost of pharmacy and cost of imaging studies.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Jun 2029, 41 months later.
Of 20 interventional studies with no phase under Pancreatitis, Acute Necrotizing, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 36. This study's planned 41 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pancreatitis, Acute Necrotizing →
Orlando Health, Inc.